Adlai Nortye Ltd. announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC in more than 180 sites around the world, spanning over 18 markets in North America, Europe, Asia, and South America. This clinical study evaluates buparlisib (AN2025), an oral pan-PI3K inhibitor, in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This represents the first global multicenter phase III trial for HNSCC in the class of PI3K inhibitors.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.575 USD | -9.44% | -34.85% | -26.86% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.86% | 268M | |
+45.57% | 54.63B | |
-7.09% | 39.92B | |
+37.07% | 38.82B | |
+12.72% | 26.86B | |
-11.17% | 26.22B | |
-22.12% | 18.78B | |
+24.80% | 12.21B | |
-0.03% | 12.16B | |
+25.20% | 11.94B |
- Stock Market
- Equities
- ANL Stock
- News Adlai Nortye Ltd.
- Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC